G1 Therapeutics' Phase 2 trial shows Trilaciclib combined with TROP2 ADC improves overall survival in mTNBC patients, with a 4-month improvement and reduced side effects.
G1 Therapeutics' Phase 2 trial results suggest Trilaciclib improves median overall survival (OS) when combined with TROP2 Antibody-Drug Conjugate (ADC) for metastatic triple negative breast cancer (mTNBC) patients. A four-month OS improvement was observed compared to historical ADC data, and Trilaciclib reduced myelosuppression and diarrhea. The findings will be presented at the 2024 ASCO Meeting.
May 28, 2024
3 Articles